Premium
Oral acyclovir for herpes zoster: a double‐blind controlled trial in normal subjects
Author(s) -
WASSILEW S. W.,
REIMLINGER S.,
NASEMANN T.,
JONES D.
Publication year - 1987
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1987.tb04930.x
Subject(s) - medicine , aciclovir , double blind , dermatology , virology , viral disease , herpesviridae , virus , pathology , alternative medicine , placebo
SUMMARY Sixty immunocompetent patients with herpes zoster of various dermatomes were treated 5 times a day for 5 days with either acyclovir at a dose of 400 mg or placebo. Acyclovir was shown to reduce significantly the time to full crusting ( P = 0.02). There were also trends in favour of acyclovir for time to first dry vesicle and time to first day without macules or papules, but these were not statistically significant. There were no differences between the groups in the occurrence of adverse events or postherpetic neuralgia.